 |
Prospector
Profile
3-11-001
|
| |
| ZIOPHARM Oncology, Inc. |
NAICS |
541710 |
| 1180 Avenue of the Americas, 19th Floor,
New York, NY 10036 |
Description |
Biotechnology |
| (646) 214-0700 |
Employees |
42 |
| http://www.ziopharm.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-26.6100 |
| |
Assets |
(mil) |
36.7300 |
| |
Liability |
(mil) |
6.3600 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
ZIOPHARM Oncology, Inc., reported a net loss of $26,608,246 for the year ended December 31, 2007, which is higher than the net losses of $17,856,919 and $9,516,922 during the years ended December 31, 2006 and 2005, respectively. As a result of its recurring losses, the Company's has an accumulated deficit of $59,829,521 as of December 31, 2007.
|
| |
|
Intellectual Property:
On August 24, 2004, the Company entered into a Patent and Technology License Agreement with The Board of Regents of the University of Texas System, acting on behalf of The University of Texas M. D. Anderson Cancer Center and the Texas A&M University System. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals for human and animal use. One of these classes includes darinaparsin. In October 2004, the Company received a notice of allowance for U.S. Patent Application No. 10/337969, entitled S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer. The patent was granted on June 28, 2005 as U.S. Patent No. 6,911,471. The patent claims both therapeutic uses and pharmaceutical compositions containing a novel class of organic arsenicals, including darinaparsin, for the treatment of cancer. In February 2006, the Company announced a second organic arsenic patent that was issued under U.S. Patent No. 6,995,188. This patent provides further coverage of cancer treatment using organic arsenic, including darinaparsin, in combination with other agents or therapies. [SEC Filing 10-KSB 02-21-2008]
|
| |
|
Description:
ZIOPHARM Oncology, Inc., engages in the development and commercialization of a portfolio of in-licensed cancer drugs.
|
| |
|
Officers:
Jonathan Lewis (CEO & Dir.); Richard Bagley (Pres., COO, CFO, Treas. & Dir.); Murray Brennan (Dir.); James Cannon (Dir.); Timothy McInerney (Dir.); Wyche Fowler, Jr. (Dir.); Gary S. Fragin (Dir.); Michael Weiser (Dir.)
|
| |
|
Auditor:
Vitale Caturano & Company Ltd.
|
| |
|
Securities:
Common Stock Symbol ZIOP; NasdaqCM; 21,298,964 common shares outstanding as of February 19, 2008.
|
| |
| |
| |
| return to main page |
|
|
